NCT05175664 (TRACK-AD) is a clinical trial of Long-term study in Alzheimer Disease, sponsored by Danish Dementia Research Centre.

Who is sponsoring NCT05175664?

NCT05175664 is sponsored by Danish Dementia Research Centre.

What drugs are being tested in NCT05175664?

Interventions in NCT05175664: Long-term study, Short-term study, Cross-sectional study.

What condition does NCT05175664 study?

NCT05175664 studies Alzheimer Disease, Mild Cognitive Impairment, Neuro-Degenerative Diseases, Vascular Dementia, Dementia With Lewy Bodies, Healthy Controls.

Is NCT05175664 still recruiting?

NCT05175664 is currently completed. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT05175664: TRACK-AD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Diagnostic and Disease Stage Biomarkers in AD

Completed Last updated 13 May 2025

What this trial tests

trial testing Long-term study in Alzheimer Disease in 350 participants. Completed in 1 December 2024.

Timeline

1 January 2022

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Danish Dementia Research Centre
Status	Completed
Study type	OBSERVATIONAL
Enrollment	350
Start date	1 January 2022
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across Denmark

Drugs / interventions tested

Long-term study
Short-term study
Cross-sectional study

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Neuro-Degenerative Diseases — all drugs for Neuro-Degenerative Diseases →
Vascular Dementia — all drugs for Vascular Dementia →

Sponsor

Danish Dementia Research Centre

Who can join

Adults 30 to 110, any sex, with Alzheimer Disease or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the efficacy of novel biomarkers, namely blood-based biomarkers, pupillometry and actigraphy to track and predict progression of Alzheimer's disease (AD). Furthermore, the study will investigate the diagnostic value of pupillometry and actigraphy for AD.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort.
Clemmensen FK, Gramkow MH, Simonsen AH, Ashton NJ, et al · · 2025 · cited 12× · PMID 39838483 · DOI 10.1186/s13195-024-01658-7
Diagnostic performance of light reflex pupillometry in Alzheimer's disease.
Gramkow MH, Clemmensen FK, Sjælland NS, Waldemar G, et al · · 2024 · cited 7× · PMID 39086497 · DOI 10.1002/dad2.12628
Diagnostic performance of actigraphy in Alzheimer's disease using a machine learning classifier - a cross-sectional memory clinic study.
Gramkow MH, Brink-Kjær A, Clemmensen FK, Sjælland NS, et al · · 2025 · cited 3× · PMID 40399918 · DOI 10.1186/s13195-025-01751-5
Prognostic value of plasma biomarkers in early Alzheimer's disease: a longitudinal clinical and neuroimaging study.
Clemmensen FK, Gramkow MH, Gonzalez-Ortiz F, Benedet AL, et al · · 2025 · cited 1× · PMID 41225647 · DOI 10.1186/s13195-025-01892-7
The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.
Clemmensen FK, Gonzalez-Ortiz F, Gramkow MH, Santos C, et al · · 2025 · cited 1× · PMID 40827127 · DOI 10.1002/trc2.70143
Prognostic value of light reflex pupillometry in Alzheimer's disease - a longitudinal cohort study.
Gramkow MH, Clemmensen FK, Lindberg U, Law I, et al · · 2025 · PMID 40646621 · DOI 10.1186/s13195-025-01794-8

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Danish Dementia Research Centre trials

Trials by the same sponsor.

NCT06621758 — Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD · not yet recruiting
NCT06567431 — Blood And Tears in Alzheimer's Disease · recruiting
NCT07355829 — DemTool - Supporting Life With Dementia · NA · completed
NCT04436341 — Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia · completed
NCT04304859 — Brief Assessment of Impaired Cognition · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05175664 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danish Dementia Research Centre
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175664.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing